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S U M M A R Y
Objective: This study aimed to investigate the clinical and microbiological features of recurrent group B
streptococcal (GBS) diseases among non-pregnant adults.
Methods: All hospitalized non-pregnant adults who had culture-proven GBS infections between January
2008 and December 2010 were enrolled in this retrospective study. Bacterial isolates were examined for
their serotypes, genotypes, and antimicrobial resistance.
Results: The recurrence rate of GBS infection in Taiwan was found to be 9.3%. Of the 70 recurrent
episodes in 32 patients, infections of the urinary tract (U) were diagnosed clinically in 55.7%, infections of
the soft tissue (S) in 31.4%, and infections of the bloodstream (B) in 12.9%. The initial/recurrent episodes
in 25 patients were mainly U/U (40.6%), followed by S/S (18.8%) and B/B (6.2%). The serotypes/serogroups
identiﬁed were serotypes V (34.3%), Ib (22.9%), VI (17.1%), III (12.9%), IV (7.1%), and Ia (5.7%). Recurrent
strains showed less resistance to erythromycin or clindamycin than non-recurrent strains. Six distinct
genotypes were identiﬁed in 12 serotype VI isolates derived from seven patients; ﬁve of these isolate
pairs had identical genotypes.
Conclusions: Recurrent GBS diseases were found to occur considerably more often than previously
thought, mainly in adults with a high comorbid index. Relapse, not new acquisition, was found to be
more common.
 2014 The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/3.0/).
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Invasive group B streptococcal (GBS) diseases in non-pregnant
adults represent a substantial and increasing health burden
worldwide, particularly in the elderly and those with comorbid-
ities.1–4 Diabetes mellitus, cirrhosis, renal failure, cancer, and
decubitus ulcers are independent risk factors for invasive GBS* Corresponding author. Tel.: +886 939946981.
** Corresponding author. Tel.: +886 975365935.
E-mail addresses: cschu@mail.ncyu.edu.tw (C. Chu),
chchiu@adm.cgmh.org.tw (C.-H. Chiu).
http://dx.doi.org/10.1016/j.ijid.2014.05.026
1201-9712/ 2014 The Authors. Published by Elsevier Ltd on behalf of International So
license (http://creativecommons.org/licenses/by-nc-nd/3.0/).diseases in non-pregnant adults.4,5 Common clinical presentations
in these patients include skin and soft tissue infections, bacter-
emia, pneumonia, and urinary tract infections.6 The worldwide
development of antimicrobial resistance to macrolides, lincosa-
mides, and ﬂuoroquinolones and the emergence of penicillin
resistance in GBS has limited the use of these antibiotics to treat
certain infections.7–9
The recurrence of GBS infections, ﬁrst reported in the mid to late
1970s, remains a rare manifestation of pediatric and adult GBS
infections.10,11 Although little is known about this phenomenon,
two population-based surveillance studies in Denmark and North
America demonstrated the recurrence rate to be 1.3% for children
and 4.3% for adults.11,12 Predicting which patients among thoseciety for Infectious Diseases. This is an open access article under the CC BY-NC-ND
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challenging. In fact, patients with recurrent GBS infections
clinically resemble patients with their ﬁrst GBS infection. Data
describing the clinical and microbiological features of recurrent
GBS infection in adults, including risk factors to predict recurrence,
are lacking. Whether a tendency exists in strain-speciﬁc char-
acteristics that contribute markedly to recurrence also remains
unknown.
This study investigated the clinical characteristics of recurrent
GBS infections, speciﬁcally with respect to grading systems that
accurately predict recurrence. This study also identiﬁed the
capsular serotypes, resistance phenotypes, and pulsed-ﬁeld gel
electrophoresis (PFGE) genotypes of the clinical isolates causing
recurrent infections.
2. Materials and methods
2.1. Patients and isolates
All hospitalized non-pregnant adults who had culture-proven
GBS infections between January 2008 and December 2010 were
enrolled in this retrospective study. A recurrent GBS infection was
deﬁned as a new culture-proven GBS infection that occurred more
than 1 month after completion of antimicrobial therapy for the
initial infection in the same individual.13 Patients with nosocomial
infections were ineligible when they had hospital-acquired GBS
infections. Clinical isolates of GBS were identiﬁed by standard
laboratory techniques, in accordance with the guidelines of the US
Centers for Disease Control and Prevention (CDC; 2010),14 at the
Department of Laboratory Medicine, Chang Gung Memorial
Hospital (CGMH), Chiayi, which is a 1300-bed tertiary care
teaching hospital located in southern Taiwan. All clinical isolates
of GBS were selected using Todd–Hewitt broth (Oxoid, UK)
supplemented with colistin (10 mg/ml) and nalidixic acid
(15 mg/ml) (bioMe´rieux, France) in order to prevent growth of
contaminants. All suspected GBS colonies (pin point, with narrow
beta-hemolysis) were sub-cultured on blood agar and subjected to
Gram staining and catalase tests. All Gram-positive and catalase-
negative cocci isolates were conﬁrmed using the Christie, Atkins,
Munch-Peterson (CAMP) test and latex agglutination assay.15 This
study was approved by the research ethics committee of CGMH.
The serotype and serogroup (ST/SG) of each isolate were
determined using a multiplex PCR assay, as described previously.16
2.2. Clinical information
The medical charts of each patient were reviewed and the
following data collected: demographics, comorbid conditions,
hospitalization history, deﬁnitive antibiotic regimens, duration of
antibiotic treatment, ﬁnal diagnosis, and outcome. The Charlson
comorbidity index (CCI) is a weighted-score scale based on the
relative risk of 19 conditions that signiﬁcantly inﬂuence out-
come.17 Patients were considered to have a comorbid condition
when they had a listed disorder in their records or were treated for
the disorder. The CCI scores were calculated by weighting each
comorbid disease independently.
2.3. Antimicrobial susceptibility
All isolates were screened for susceptibility to erythromycin
and clindamycin using double disk diffusion tests. Macrolide–
lincosamide–streptogramin B (MLSB) phenotypes were character-
ized as described previously.18 Macrolide phenotypes (M) were
categorized by susceptibility to clindamycin without blunting
inhibition zones around the clindamycin disk. The minimum
inhibitory concentration (MIC) of dalfopristin was applied toidentify the lincosamide–streptogramin A (LSA) phenotypes in
isolates with erythromycin susceptibility and clindamycin resis-
tance. Resistance to erythromycin, clindamycin, and dalfopristin
was identiﬁed using the agar dilution method with the breakpoints
of the Clinical and Laboratory Standards Institute.19
2.4. DNA preparation and PFGE
Macrofragments of genomic DNA from serotype VI isolates,
digested with SmaI (New England BioLabs, Frankfurt, Germany),
were analyzed by pulsed-ﬁeld gel electrophoresis (PFGE), as
described previously.20 The total number of visible bands was
counted for each isolate, and patterns were compared visually.
Genotypes and subtypes were veriﬁed using the criteria of Tenover
et al.21
2.5. Statistical analysis
Categorical data were analyzed using the Chi-square test or
Fisher’s exact test. Continuous variables were analyzed using the
Student’s t-test. Univariate and multivariate logistic regression
analysis was used to discriminate independent risk factors of
comorbid conditions. All data were analyzed using IBM–SPSS v.
20.0 software (IBM Corp., Armonk, NY, USA). Two-sided p-values
<0.05 were considered to be statistically signiﬁcant.
3. Results
3.1. Demographics
In total, 345 individuals had 383 episodes of GBS infection, and
recurrent infections were detected in 32 patients (70 episodes);
thus, the recurrence rate was 9.3% (32/345). The mean age of the
345 patients was 57.7 years (range 18–92 years) when they had
their ﬁrst GBS infection (Table 1). No difference in gender
distribution was found between the two groups of patients.
3.2. Comorbid conditions
In total, 165 (47.8%) of the 345 patients had a CCI score 1. The
most common comorbid condition encountered in recurrence was
diabetes (31.2%), followed by diabetes with end-organ damage
(18.8%), peptic ulcer disease (15.6%), any prior tumor (9.4%), and
moderate to severe renal disease (9.4%) (Table 1). Although
diabetes with end-organ damage was a risk factor for recurrence (p
= 0.012), multivariate analysis showed that diabetic patients with
and without end-organ damage had a higher risk for recurrent
infections than non-diabetic patients (16.7% (16/96) vs. 6.4% (16/
249); p = 0.003) (odds ratio 2.913, 95% conﬁdence interval 1.392–
6.092; p = 0.005) (data not shown).
The weighted scores of all comorbid conditions were summed
and then scaled to the CCI. The mean CCI of recurrence patients was
signiﬁcantly higher than that of non-recurrence patients (1.88 
1.91 vs. 1.11  1.58; p = 0.011).
3.3. Clinical diagnosis and time intervals
The clinical diagnosis of the 70 recurrent infections was
39 urinary tract infections (55.7%) (U), 22 soft tissue infections
(31.4%) (S), and nine bloodstream infections (12.9%) (B) (Table 2).
Twenty-ﬁve (78.1%) of the 32 patients had similar clinical
presentations for consecutive episodes of GBS infection, mainly
U/U (40.6%), followed by S/S (18.8%), B/B (6.2%), S/B (6.2%), U/U/U
(6.2%), and S/S/S (6.2%). Primary bacteremia was found in patients
in the B/B, U/B, and U/U/B groups. Soft tissue infection with
bacteremia was categorized into the bloodstream infection (B)
Table 1
Demographics and Charlson comorbidity index (CCI) scores for the 345 patients with GBS infection
Total, n (%)
(N = 345)
Recurrent, n (%)
(n = 32)
Non-recurrent, n (%)
(n = 313)
p-Value
Demographics
Age, years, mean  SD 57.7  15.1 59.2  14.3 57.6  15.1 0.568
Male, n (%) 115 (33.3) 14 (43.8) 101 (32.3) 0.189
Charlson comorbidity index, n (%)
Diabetes 70 (20.3) 10 (31.2) 60 (19.2) 0.106
Peptic ulcer disease 38 (11.0) 5 (15.6) 33 (10.5) 0.374
Chronic pulmonary disease 29 (8.4) 2 (6.2) 27 (8.6) 0.644
Mild liver disease 20 (5.8) 2 (6.2) 18 (5.8) 0.707
Dementia 15 (4.3) 2 (6.2) 13 (4.2) 0.580
Coronary artery disease 14 (4.1) 2 (6.2) 12 (3.8) 0.379
Cerebrovascular disease 13 (3.8) 1 (3.1) 12 (3.8) 1.000
Congestive heart failure 4 (1.2) 1 (3.1) 3 (1.0) 0.324
Connective tissue disease 4 (1.2) 1 (3.1) 3 (1.0) 0.324
Peripheral vascular disease 1 (0.3) 0 (0.0) 1 (0.3) 1.000
Any prior tumor (within 5 years of diagnosis) 27 (7.8) 3 (9.4) 24 (7.7) 0.728
Diabetes with end-organ damage 26 (7.5) 6 (18.8) 20 (6.4) 0.012
Moderate to severe renal disease 18 (5.2) 3 (9.4) 15 (4.8) 0.227
Hemiplegia 3 (0.9) 1 (3.1) 2 (0.6) 0.254
Leukemia 0 (0.0) 0 (0.0) 0 (0.0)
Lymphoma 1 (0.3) 1 (3.1) 0 (0) 0.093
Moderate to severe liver disease 13 (3.8) 2 (6.2) 11 (3.5) 0.344
Metastatic solid tumor 2 (0.6) 0 (0.0) 2 (0.6) 1.000
AIDS (not only HIV-positive) 0 (0.0) 0 (0.0) 0 (0.0)
Total of CCI (mean) 1.2  1.6 1.9  1.9 1.1  1.6 0.011
GBS, group B Streptococcus; SD, standard deviation.
Table 2
Clinical diagnosis and time intervals between consecutive infections in 32 patients with 70 episodes of infection
Diagnosis of consecutive episodesa (n = 32 patients; 70 episodes) Time intervals
(days)
U/U S/S B/B S/B S/U U/B U/S U/U/U S/S/S U/U/B B/U/U
Total (n = 32; 70 episodes) 13 (40.6) 6 (18.8) 2 (6.2) 2 (6.2) 1 (3.1) 1 (3.1) 1 (3.1) 2 (6.2) 2 (6.2) 1 (3.1) 1 (3.1) 91.0  96.1
Concordant
serotype
(n = 26; 57 episodes)
9 (34.6) 6 (23.1) 2 (7.7) 1 (3.8) 1 (3.8) 1 (3.8) 1 (3.8) 2 (7.7) 2 (7.7) 1 (3.8) 0 (0.0) 76.2  84.6
Discordant serotype
(n = 6; 13 episodes)
4 (66.7) 0 (0.0) 0 (0.0) 1 (16.7) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (16.7) 156.4  122.5
p-Value 0.194 0.564 1.000 0.345 1.000 1.000 1.000 1.000 1.000 1.000 0.188 0.044
a U, urinary tract infection; S, soft tissue infection; B, bloodstream infection.
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from a soft tissue infection. No deep tissue infection such as
necrotizing fasciitis was found in the soft tissue infection (S)
group.
The length of deﬁnitive antimicrobial treatment (penicillins or
cephalosporins), depending on the infection type, was 7–36 days
(median 17 days) for the ﬁrst infection (18 U, 11 S, and 3 B), 6–29
days (median 13 days) for the second infection (18 U, 9 S, and 5 B),
and 7–30 days (median 14 days) for the third infection (3 U, 2 S,
and 1 B).
For the 38 time intervals between consecutive episodes of
disease recurrence, the mean duration of the time intervals was
90.97  96.08 days (range 32–384 days). Concordant ST/SG,
responsible for 81.3% (26/32) of recurrent infections, had a
signiﬁcantly shorter time interval than discordant ST/SG (76.19 
84.62 days vs. 156.43  122.46 days; p = 0.044).
3.4. Serotype/serogroup
Regarding the 383 isolates, the prevalence of ST/SGs was as
follows: V 29.5%, Ib 23.8%, III 15.1%, VI 9.4%, IV 8.6%, Ia 5.0%, II 3.9%,
non-typeable 3.7%, and VII 1.0% (Table 3). Likely due to small
numbers of isolates, serotypes II, VII, and the non-typeable were
not identiﬁed in recurrent strains. Recurrence was not correlatedwith any speciﬁc ST/SG, except that serotype VI accounted for
17.1% of recurrent strains and 7.7% of non-recurrent strains (p =
0.014).
3.5. Resistance phenotypes and genotype analysis
All clinical isolates remained susceptible to penicillin; however,
59.8% (229/383) and 59.3% (227/383) of isolates had resistance to
erythromycin and clindamycin, respectively (Table 4). Somewhat
surprisingly, recurrent strains had a lower rate of resistance to
erythromycin or clindamycin (51.4%) than non-recurrent strains
(66.1%) (p = 0.021). Analysis of resistance phenotypes among the
243 resistant strains of recurrent and non-recurrent origin
indicated that the MLSB phenotype accounted for 55.6%, the M
phenotype for 4.2%, and the LSA phenotype for 3.7%. Moreover, M
phenotype and LSA phenotype were not detected in recurrent
strains.
This study applied SmaI-digested PFGE analysis to the 12 strains
of serotype VI (derived from seven individuals with recurrent
infection). These patients were classiﬁed into three major
genotypes containing six subtypes, each comprising eight or nine
fragments ranging from approximately <48.5 kb to 533.5 kb
(Figure 1). Speciﬁcally, ﬁve isolate pairs from ﬁve individuals
(patients 1–5) had the same genotype. Of the remaining two
Table 4
Prevalence of resistance phenotypes of 383 isolates collected from 345 patients with GBS infection
Susceptibility to erythromycin/clindamycin (resistance phenotypes)
R/R (MLSB phenotype)
a R/S (M phenotype)b S/R (LSA phenotype)c S/S
Total (n; % of 383) 213 (55.6) 16 (4.2) 14 (3.7) 140 (36.6)
Recurrent (n; % of 70) 36 (51.4) 0 (0.0) 0 (0.0) 34 (48.6)
Non-recurrent (n; % of 313) 177 (56.5) 16 (5.1) 14 (4.5) 106 (33.9)
p-Value 0.436 0.051 0.083 0.021
GBS, group B Streptococcus; R, resistant; S, susceptible.
a MLSB: macrolide–lincosamide–streptogramin B.
b M: macrolide.
c LSA: lincosamide–streptogramin A.
Table 3
Distribution of GBS capsular serotypes of 383 isolates collected from 345 patients with GBS infection
Serotype
Ia Ib II III IV V VI VII Non-typeable
Total isolates
(n; % of 383)
19 (5.0) 91 (23.8) 15 (3.9) 58 (15.1) 33 (8.6) 113 (29.5) 36 (9.4) 4 (1.0) 14 (3.7)
Recurrent
(n; % of 70)
4 (5.7) 16 (22.9) 0 (0.0) 9 (12.9) 5 (7.1) 24 (34.3) 12 (17.1) 0 (0.0) 0 (0.0)
Non-recurrent
(n; % of 313)
15 (4.8) 75 (24.0) 15 (4.8) 49 (15.7) 28 (8.9) 89 (28.4) 24 (7.7) 4 (1.3) 14 (4.5)
p-Value 0.761 0.844 0.084 0.555 0.627 0.332 0.014 1.000 0.083
GBS, group B Streptococcus.
Figure 1. PFGE analysis of 12 strains of serotype VI (derived from seven individuals
with recurrence). M: lambda ladder marker; lanes 1–12: strains 58, 59, 443, 447,
292, 405, 489, 491, 419, 427, 219, and 431. S: soft tissue infection; U: urinary tract
infection; B: bloodstream infection. Pulsotype: three major genotypes (I–III)
contained a total of six subtypes, each comprising eight or nine fragments ranging
from approximately <48.5 kb to 533.5 kb. Five isolate pairs belonging to ﬁve
individuals (patients 1–5) were genotypically identical.
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consecutive infections were U/U (III/VI) and U/U (VI/V), and time
intervals were 163 days and 32 days, respectively.
4. Discussion
Until recently, little data existed in terms of risk factors for
recurrent GBS infection among adults, although diabetes mellitus,
cirrhosis, and renal failure have each been associated with a single
GBS infection in some population-based studies.4 Patients who
suffered from recurrent GBS infection in this study were likely tohave diabetes, a peptic ulcer, chronic pulmonary diseases, any
prior tumor, and diabetes with end-organ damage. Diabetes with
or without end-organ damage is an independent risk factor for
recurrence, as it was for the initial GBS infection.4,5 Nevertheless,
no clinical features were identiﬁed in this study that could be used
to distinguish those patients with recurrence from those who do
not develop a recurrent infection. Even if diabetes with or without
end-organ damage is the best clinical clue for identifying patients
likely to develop recurrence, the common occurrence of diabetes
and the low rate of recurrent GBS infection in the community limits
its predictive value.
Analytical results showed a substantially higher CCI score in
patients with a recurrent infection than in patients without a
recurrent infection, suggesting that the CCI predicts the recurrence
of GBS infection better than individual comorbidity conditions.
Physicians must pay special attention to those patients who have
one episode of GBS infection and a high CCI score because they are
at higher risk of recurrence. This is the ﬁrst report to speciﬁcally
validate the use of the CCI to predict the recurrence of GBS
infection.
In a national survey of non-pregnant adults with a single GBS
infection, the most common clinical diagnosis was skin, soft tissue,
and bone infections (36%), followed by bacteremia (30%), urinary
tract infections (14%), pneumonia (9.5%), and peritonitis (7.3%).2
This study showed that nearly half of the recurrent infections were
urinary tract infections (55.7%, 39/70 episodes), mainly U/U (40.6%,
13/32 patients). Despite the limited number of cases, the results
suggest that GBS is a uropathogen and that GBS can cause a
recurrent urinary tract infection by unknown mechanisms.22
Several investigations have demonstrated the time to second
infection to be short when recurrent infection is caused by the
same serotype responsible for the ﬁrst infection.10,11 Data in this
study are in agreement with those reported in the aforementioned
studies; concordant serotypes were often isolated from patients
whose initial infection was relatively recent (mean interval
between the initial and recurrent infection was 76.2 days),
whereas discordant serotypes were identiﬁed in those with a
longer interval between the two infections (mean duration 156.4
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consecutive infections may imply a relapse of the ﬁrst infection.
From the analytical results, we speculate that the second
infections were most often attributable to either incomplete
treatment of the initial infection or treatment failure. In fact, each
patient in this study was given antimicrobial therapy with what is
now considered, depending on the infection type, an appropriate
drug, dosage, and duration. Regimens (penicillins or cephalospor-
ins) as well as the duration (7–36 days) of antimicrobial therapy for
patients with an initial infection was likely adequate for symptom
relief, but not necessarily for eradication, resulting in subsequent
relapse. The extension of therapy beyond the currently recom-
mended duration for GBS infection in an attempt to eradicate the
infection is not recommended. Thus, GBS eradication in high-risk
patients with GBS infection remains challenging.23
At least nine recognizable serotypes (Ia, Ib, and II–VIII) exist in
GBS, and serotype IX has recently been identiﬁed.24 The prevalent
ST/SG of GBS causing invasive infection usually varies over time
and among different populations.4,6 Since 1996, serotype V has
been the predominant serotype (29.0–47.7%) for non-pregnant
adults in North America, Asia, and Africa who have a single GBS
infection.25–27 In Taiwan, type V (27.1–32.5%) and type III (20.0–
28.5%) are the most widespread ST/SGs of GBS.26,28,29 Consistent
with previous surveillance data, serotype V accounted for 34.3% of
serotypes in recurrent strains and 28.4% in non-recurrent strains in
this study. A striking ﬁnding was the high prevalence of serotype Ib
in both recurrent (22.9%) and non-recurrent strains (24.0%); this
serotype is currently rare in North America and Europe.2,3,12 Based
on a prior investigation, this remarkable increase in serotype Ib is
likely correlated with clonal spread in Taiwan.30
This investigation is unique in that a limited number of ST/SGs
were found to be disproportionately associated with disease
recurrence; serotype VI, for example, was typically associated with
recurrent infection. This implies that serotype VI may be more
virulent than other serotypes. Further epidemiological studies are
needed to determine whether this ST/SG distribution of GBS is
restricted to Taiwan.
Despite the wide use of penicillin-based regimens, GBS isolates
are usually susceptible to penicillin.8 However, resistance to
antimicrobials used as alternative therapy, especially macrolides,
lincosamides, and ﬂuoroquinolones, has been documented in-
creasingly.7,9 In the USA, recently published data on GBS
bacteremia in adults during 2002 to 2010 revealed that erythro-
mycin and clindamycin resistance occurred in 43.6% and 39.7% of
cases, respectively.31 The high prevalence of resistance to
erythromycin and clindamycin (59.8% and 59.3%, respectively)
in this study was very similar to that reported in a prior survey
(58.3% and 57.9%, respectively) from Taiwan for the period 2006–
2008.30
Conversely, this study showed that recurrent strains typically
had a lower rate of resistance to erythromycin or clindamycin.
Genetic changes that account for antibiotic resistance in micro-
organisms also alter virulence to some degree.7,32,33 Thus, we
speculate that non-resistant recurrent strains might be more prone
to acquiring virulence traits which may be a survival advantage to
microorganisms.34–36
The MLSB phenotype was the predominant resistance pheno-
type found in recurrent and non-recurrent strains. Genotyping
highlighted the fact that ribosomal modiﬁcation by methylases,
encoded by erm genes, plays a major role in macrolide resistance
for GBS in Taiwan. This observation differs from results reported in
England and Wales and North America,37,38 in which M resistance
mechanisms were found, usually involving drug efﬂux by
membrane-bound protein encoded in mef genes.
Considerable variation in genetic content was found to exist
among strains of serotype VI, implying that the increase inserotype VI in recurrent strains was not due to the dissemination of
a few clones in Taiwan. This observation is of epidemiological
signiﬁcance. Further surveillance of clonal heterogeneity in GBS
isolates by different measures is necessary. On the other hand,
serotyping and genotyping of GBS strains conﬁrmed that the
recurrent GBS infection in ﬁve of the seven patients was caused by
the same strain and not a newly acquired strain. Recurrent GBS
infection due to bacterial reinvasion from a colonizing site has
been identiﬁed in a few studies, although most were limited to
pregnant women or neonates.10,39,40 Harrison et al. (1995), using
restriction endonuclease analysis of chromosomal DNA, ﬁrst
determined that 13 of 18 adults were infected by concordant
ST/SGs and also genotypically identical GBS strains.11 Data in this
study suggest that recurrent GBS infection should result from
relapse of a previous infection.
This study has several limitations. First, it had a cross-sectional
design. The 9.3% recurrent infection rate in this hospital-based
survey exceeds rates previously reported. The rates of recurrence
may increase steadily over time in a longitudinal study. Thus, the
cumulative incidences of recurrent GBS infection may be under-
estimated in this cross-sectional study. The second limitation is
that the isolates examined were not population-based and,
therefore, may not reﬂect collective bias. Thirdly, there is a
possibility of potential misclassiﬁcation bias as patients with
recurrence may not have attended the same hospital, or patients
may not have been hospitalized for the ﬁrst episode and thus not
classiﬁed as recurrences.
This snapshot of recurrent GBS infections showed that they
occur more frequently than previously thought, despite appropri-
ate antimicrobial therapy, mainly in adults with a high comorbidi-
ty index. This is the ﬁrst study to systematically examine the host-
and strain-speciﬁc characteristics of recurrent GBS infections. The
results indicate that relapse is the major cause of disease
recurrence. The development of new treatment modalities to
eradicate site-speciﬁc colonization, thereby preventing future
relapse, would beneﬁt patients.
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